Edition:
United States

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

1.97USD
3:59pm EST
Change (% chg)

$-0.23 (-10.45%)
Prev Close
$2.20
Open
$2.16
Day's High
$2.16
Day's Low
$1.97
Volume
2,895
Avg. Vol
23,484
52-wk High
$12.48
52-wk Low
$1.77

Summary

Name Age Since Current Position

Jeffrey Bailey

55 2018 Chairman of the Board

Manuel Aivado

48 2018 President, Chief Executive Officer, Director

Evan Lippman

2015 Chief Financial Officer and Business Officer, Senior Vice President

D. Allen Annis

2018 Senior Vice President - Research

Vojislav Vukovic

2018 Chief Medical Officer

Seth Harrison

57 2016 Director

Biographies

Name Description

Jeffrey Bailey

Mr. Jeffrey A. Bailey is Chairman of the Board of the Company. Mr. Bailey currently serves as interim Chief Executive Officer and director of IlluminOss, Inc., a medical device company developing and marketing orthopedic fracture repair products, a position he has held since January 2018. Previously, he served as Executive Chairman of Neurovance, Inc., a private clinical-stage pharmaceutical company, beginning in December 2015, and Chief Executive Officer of Neurovance, Inc. beginning in November 2016, until its acquisition by Otsuka Pharmaceutical Co., Ltd., which was announced in March 2017. From January 2013 through June 2015, Mr. Bailey also served as President and Chief Executive Officer and director of Lantheus Medical Imaging, Inc., a public company providing diagnostic imaging agents. Prior to 2013, Mr. Bailey held various leadership positions with several public and private pharmaceutical and medical device companies, including operating unit President at Novartis Pharmaceuticals and a 22-year career with Johnson & Johnson (including Janssen Pharmaceutica NV).

Manuel Aivado

Mr. Manuel C. Aivado is President, Chief Executive Officer, Director of the Company. He has served as our Senior Vice President, Chief Medical Officer since September 2014. From March 2012 until September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 until March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. In addition, Dr. Aivado was an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years, during which time he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology and medical oncology, and he received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany. The Company believes that Dr. Aivado is qualified to serve on its Board due to his extensive knowledge of the Company and his significant background in pharmaceutical research and development.

Evan Lippman

Mr. Evan Lippman is Chief Financial Officer and Business Officer, Senior Vice President of the Company. He began his career in corporate finance and investment banking, managing equity, debt and M&A processes, working with such companies as Bank of America, and Bear Stearns. Prior to joining Aileron, Mr. Lippman was Senior Vice President at EMD Serono, Inc., leading the strategic direction of the US Neurology franchise, as well as managing its operations related to sales, marketing and support services. Mr. Lippman joined EMD Serono from AstraZeneca, where he served as Executive Director of the company’s multi-billion dollar brands, Crestor® and Nexium®, as well as the general Primary Care Portfolio. While at AstraZeneca, Mr. Lippman also held other roles including Head of US Business Development. Prior to AstraZeneca, he worked at Pfizer as Executive Director, Worldwide Business Development and Strategic Planning. Mr. Lippman holds a Bachelor of Arts in Political Science from Bucknell University, a Bachelor of Arts in Business from Georgia State University, and a Masters in Business Administration from Cornell University.

D. Allen Annis

Dr. D. Allen Annis, Ph.D. is the Vice President - Biophysical and Analytical Technologies of Aileron Therapeutics, Inc. He has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions. Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.

Vojislav Vukovic

Mr. Vojislav Vukovic is Chief Medical Officer of the Company. Dr. Vukovic is a pharmaceutical industry executive with 20 years of hands-on experience in oncology drug development and medical affairs. Most recently, he was the CMO of Taiho Oncology, where he oversaw the reorganization and scaling of the U.S. and European R&D function to advance the development of the company's clinical programs. Prior to Taiho, Dr. Vukovic held the CMO role at Synta Pharmaceuticals Inc. where he oversaw the company's clinical programs, as well as biometrics, clinical operations, pharmacovigilance, regulatory and medical affairs. During his tenure at Synta, Dr. Vukovic led many early and late-stage clinical trials and their translational research activities, including biomarker discovery and validation. Prior to Synta, Dr. Vukovic was a Medical Director at Pfizer, where he was responsible for the development of sunitinib and axitinib in several oncology indications. He also was a member of the leadership team for Pfizer's Oncology Radiotherapy Initiative.

Seth Harrison

Dr. Seth L. Harrison, M.D. is the Director of Aileron Therapeutics, Inc. He is the Founder and Managing General Partner of Apple Tree Partners. He serves on the Board of Directors of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides. Dr. Harrison received a Bachelor of Arts from Princeton University, a Doctor of Medicine and Master of Business Administration from Columbia University and completed a surgery internship at the New York Presbyterian Hospital.

Basic Compensation

Options Compensation